期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 80, 期 3, 页码 342-350出版社
WILEY
DOI: 10.1111/bcp.12668
关键词
clarithromycin; cytochrome P450-3A; drug-drug interactions; itraconazole; ketoconazole; ritonavir
AimsThe regulatory prohibition of ketoconazole as a CYP3A index inhibitor in drug-drug interaction (DDI) studies has compelled consideration of alternative inhibitors. MethodsThe biomedical literature was searched to identify DDI studies in which oral midazolam (MDZ) was the victim, and the inhibitory perpetrator was either ketoconazole, itraconazole, clarithromycin, or ritonavir. The ratios (R-AUC) of total area under the curve (AUC) for MDZ with inhibitor divided by MDZ AUC in the control condition were aggregated across individual studies for each inhibitor. ResultsMean ( SE) R-AUC values were: ketoconazole (15 studies, 131 subjects), 11.5 (+/- 1.2); itraconazole (five studies, 48 subjects), 7.3 (+/- 1.0); clarithromycin (five studies, 73 subjects), 6.5 (+/- 10.9); and ritonavir (13 studies, 159 subjects), 14.5 (+/- 2.0). Differences among inhibitors were significant (F = 5.31, P < 0.005). R-AUC values were not significantly related to inhibitor dosage or to duration of inhibitor pre-exposure prior to administration of MDZ. ConclusionsRitonavir produces CYP3A inhibition equivalent to or greater than ketoconazole, and is the best index CYP3A inhibitor alternative to ketoconazole. Cobicistat closely resembles ritonavir in structure and function, and can also be considered. Itraconazole and clarithromycin are not suitable alternatives since they do not produce inhibition comparable with ketoconazole or ritonavir, and have other significant disadvantages as well.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据